EBLN2 Inhibitors
EBLN2 inhibitors comprise a diverse array of chemical compounds that reduce the functional activity of EBLN2 through various targeted cellular signaling pathways. PD 98059 and U0126, both MEK inhibitors, decrease EBLN2 activity by impeding the MAPK/ERK pathway, where EBLN2 is considered to be a downstream signaling molecule. Similarly, LY 294002 and Wortmannin, as PI3K inhibitors, diminish the activity of EBLN2 by obstructing the PI3K/Akt pathway, which is known to modulate functions potentially regulated by EBLN2. Rapamycin, targeting mTOR signaling, and SB 203580, a p38 MAPK inhibitor, further suppress EBLN2 activity by their respective interference in the mTOR and p38 MAPK pathways, both of which are crucial for the regulation of processes that may involve EBLN2. Additionally, SP600125, by inhibiting JNK, attenuates EBLN2's activity, considering the JNK pathway's involvement in cellular functions that could implicate EBLN2.
Further contributing to the array of EBLN2 inhibitors are compounds like LFM-A13 and Dasatinib, which target BTK and Src family kinases, respectively. The inhibition of these kinases by LFM-A13 and Dasatinib leads to a decrease in EBLN2 activity, giventhe protein's potential role in signaling pathways associated with B cell receptor and Src kinase signaling. GW 5074 and Sorafenib, both acting as Raf kinase inhibitors, indirectly lower EBLN2 function through their suppression of the MAPK/ERK signaling pathway, which is upstream of where EBLN2 is posited to act. PP 2, another Src kinase inhibitor, supports the diminished activity of EBLN2 by hindering Src kinase signaling, thereby affecting EBLN2-related pathways. Collectively, these inhibitors, through their specific and targeted actions on distinct signaling pathways, achieve a cumulative effect of reducing EBLN2's functional activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
A MEK inhibitor that specifically blocks the MAPK/ERK pathway. Inhibition of this pathway diminishes EBLN2 activity, as EBLN2 is involved in the downstream signaling of ERK which affects various cellular responses. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
A selective inhibitor of MEK1/2, which impairs the MAPK/ERK pathway. Since EBLN2 is a downstream effector in this pathway, its functional activity is decreased as a result of the pathway's inhibition. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A potent inhibitor of the PI3K/Akt pathway. By blocking PI3K signaling, LY 294002 indirectly decreases EBLN2 activity which is modulated by Akt-mediated signaling events. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor that hinders the mTORC1 and mTORC2 complexes. EBLN2 function is indirectly reduced due to the role of mTOR in regulating protein synthesis and cell growth where EBLN2 may be implicated. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A p38 MAPK inhibitor, which disrupts the p38 MAPK signaling pathway. This inhibition can lead to a decrease in EBLN2 activity, given its potential interaction with p38 MAPK-dependent processes. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of c-Jun N-terminal kinase (JNK), which affects the JNK signaling pathway. EBLN2 activity is indirectly diminished since JNK pathway influences various cellular functions including those potentially involving EBLN2. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
A covalent inhibitor of PI3K, leading to suppression of the PI3K/Akt pathway. As EBLN2 function may be regulated by PI3K/Akt signaling, Wortmannin indirectly decreases EBLN2 activity. | ||||||
LFM-A13 | 62004-35-7 | sc-203623 sc-203623A | 10 mg 50 mg | $119.00 $670.00 | ||
A selective inhibitor of Bruton's tyrosine kinase (BTK), which plays a role in B cell receptor signaling. Since EBLN2 could be implicated in B cell function, LFM-A13 indirectly diminishes EBLN2 activity by inhibiting BTK. | ||||||
GW 5074 | 220904-83-6 | sc-200639 sc-200639A | 5 mg 25 mg | $106.00 $417.00 | 10 | |
A potent inhibitor of Raf-1 kinase, which is upstream of the MAPK/ERK pathway. EBLN2, being a downstream component in this pathway, experiences reduced activity due to GW 5074's action. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
A multi-kinase inhibitor that targets Raf kinases, among others. By inhibiting Raf, Sorafenib indirectly decreases EBLN2 activity through its role in the MAPK/ERK signaling pathway. | ||||||